The IGF hormonal network in endometrial cancer: Functions, regulation, and targeting approaches

Frontiers in Endocrinology

Volumn 5, Issue MAY, 2014, Pages

  Bruchim, Ilan ^a   Sarfstein, Rive ^b   Werner, Haim ^b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biomarkers; BRCA1; Endometrial cancer; IGF1; IGF1 receptor; Insulin like growth factors; P53; Uterine serous carcinoma

Indexed keywords

CARBOPLATIN; CP 751 871; DOCETAXEL; DUSIGITUMAB; ERLOTINIB; ESTRADIOL; FIBROBLAST GROWTH FACTOR 2; FIGITUMUMAB; GANITUMAB; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR SUBSTRATE 1; LINSITINIB; NVP AEW 541; PACLITAXEL; PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN C; VORINOSTAT; ZINC FINGER PROTEIN;

APOPTOSIS; BODY MASS; CANCER RISK; CANCER STAGING; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; DISEASE COURSE; DNA REPLICATION; DOWN REGULATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HORMONAL THERAPY; HORMONE RECEPTOR INTERACTION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; MENSTRUAL CYCLE; NONHUMAN; OBESITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TUMOR GROWTH; UPREGULATION; UTERINE CERVIX CANCER;

EID: 84905493633     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00076     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin (2009) 59:225-49. doi: 10.3322/caac.20006
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol (1983) 15:10-7. doi:10.1016/0090-8258(83)90111-7
3. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch (2004) 444:213-23. doi:10.1007/s00428-003-0947-3
4. Boruta DM, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler WC Jr, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer (2004) 101:2214-21. doi:10.1002/cncr.20645
5. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol (2012) 13:e353-61. doi:10.1016/S1470-2045(12)70213-9
6. Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, et al. Biomarkers in endometrial cancer: possible clinical applications. Oncol Lett (2012) 3:1175-80.
7. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor a-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol (2008) 199:.e1-7. doi:10.1016/j.ajog.2008.04.043
8. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res (2000) 6:153-9.
9. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol (1999) 17:1382-90.
10. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol (2006) 24:2376-85. doi:10.1200/JCO.2005.03.4827
11. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol (2011) 29:3278-85. doi:10.1200/JCO.2010.34.1578
12. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab (2007) 3:302-10. doi:10.1038/ncpendmet0427
13. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol (2010) 28:4985-95. doi:10.1200/JCO.2009.27.5040
14. Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med (1957) 49:825-36.
15. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer (2003) 107:873-7. doi:10.1002/ijc.11487
16. LeRoith D, Bondy C, Yakar S, Liu J-L, Butler A. The somatomedin hypothesis: 2001. Endocr Rev (2001) 22:53-74. doi:10.1210/edrv.22.1.0419
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 8:915-28. doi:10.1038/nrc2536
18. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2007) 28:20-47. doi:10.1210/er.2006-0001
19. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem (2009) 115:58-71. doi:10.1080/13813450902783106
20. Hirano S, Ito N, Takahashi S, Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol (2004) 25:187-91.
21. McCampbell AS, Broaddus RR, Loose DS, Davies PJA. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res (2006) 12:6373-8. doi:10.1158/1078-0432.CCR-06-0912
22. Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, et al. p53 regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. Eur J Cancer (2012) 48:1570-80. doi:10.1016/j.ejca.2011.09.014
23. Amichay K, Kidron D, Attias-Geva Z, Schayek H, Sarfstein R, Fishman A, et al. BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines. Int J Gynecol Cancer (2012) 22:748-54. doi:10.1097/IGC.0b013e318254011f
24. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer (2006) 106:2376-81. doi:10.1002/cncr.21866
25. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 4:579-91. doi:10.1038/nrc1408
26. Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene (2012) 31:2703-14. doi:10.1038/onc.2011.447
27. Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 13:381-406. doi:10.1007/s10911-008-9099-z
28. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer (2011) 18:R125-47. doi:10.1530/ERC-11-0074
29. Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, et al. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J (1997) 44:419-24. doi:10.1507/endocrj.44.419
30. Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E, Trichopoulos D. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology (2003) 64:341-5. doi:10.1159/000070291
31. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 17:921-9. doi:10.1158/1055-9965.EPI-07-2686
32. Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks T. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer (2003) 89:1697-704. doi:10.1038/sj.bjc.6601312
33. Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (2012) 4:580-9.
34. Pavelic J, Radakovic B, Pavelic K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol (2007) 105:727-35. doi:10.1016/j.ygyno.2007.02.012
35. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 13:787-96. doi:10.1210/me.13.5.787
36. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem (1990) 265:21172-8.
37. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K, et al. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol (1989) 3:1701-9. doi:10.1210/mend-3-11-1701
38. Zhu L, Pollard JW. Estradiol-17ß regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc Natl Acad Sci U S A (2007) 104:15847-51. doi:10.1073/pnas.0705749104
39. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem (2006) 99:392-401. doi:10.1002/jcb.20929
40. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res (2002) 62:2942-50.
41. Schayek H, Seti H, Greenberg NM, Werner H, Plymate SR. Differential regulation of IGF1-R gene transcription by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol (2010) 323:239-45. doi:10.1016/j.mce.2010.04.017
42. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 65:1849-57. doi:10.1158/0008-5472.CAN-04-1837
43. Pengchong H, Tao H. Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol (2011) 32:660-4.
44. Soufla G, Sifakis S, Spandidos DA. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Cancer Lett (2008) 259:146-55. doi:10.1016/j.canlet.2007.10.002
45. Werner H, Karnieli E, Rauscher FJ III, LeRoith D. Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A (1996) 93:8318-23. doi:10.1073/pnas.93.16.8318
46. Werner H, Bruchim I. IGF-1 and BRCA1 signaling pathways in familial cancer. Lancet Oncol (2012) 13:537-44. doi:10.1016/S1470-2045(12)70362-5
47. Maor SB, Abramovitch S, Erdos MR, Brody LC, Werner H. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab (2000) 69:130-6. doi:10.1006/mgme.1999.2958
48. Abramovitch S, Glaser T, Ouchi T, Werner H. BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett (2003) 541:149-54. doi:10.1016/S0014-5793(03)00315-6
49. Abramovitch S, Werner H. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. Horm Metab Res (2003) 35:758-62. doi:10.1055/s-2004-814154
50. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-I receptor levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett (2007) 257:236-43. doi:10.1016/j.canlet.2007.07.019
51. Bruchim I, Amichay K, Kidron D, Attias Z, Biron-Shental T, Drucker L, et al. BRCA-1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer (2010) 20:1148-53. doi:10.1111/IGC.0b013e3181ef622d
52. Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody B, et al. Ganitumab (AMG 479) inhibits IGF2-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res (2014). doi:10.1158/1078-0432.CCR-13-3448
53. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer (2010) 103:332-9. doi:10.1038/sj.bjc.6605767
54. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res (2012) 72:3-12. doi:10.1158/0008-5472.CAN-11-0550
55. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today (2005) 10:1041-7. doi:10.1016/S1359-6446(05)03512-9
56. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials - early lessons. J Mammary Gland Biol Neoplasia (2008) 13:471-83. doi:10.1007/s10911-008-9104-6
57. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell (2004) 5:231-9. doi:10.1016/S1535-6108(04)00051-0
58. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res (2011) 71:1029-40. doi:10.1158/0008-5472.CAN-10-2274
59. Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets (2013) 17:307-20. doi:10.1517/14728222.2013.749863
60. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res (2012) 18:40-50. doi:10.1158/1078-0432.CCR-11-0998
61. Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res (2011) 17:3993-4005. doi:10.1158/1078-0432.CCR-10-2243
62. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 8:909-15. doi:10.4161/cc.8.6.7933
63. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol (2010) 116:92-8. doi:10.1016/j.ygyno.2009.09.024
64. Dong L, Zhou Q, Zhang Z, Zhu Y, Duan T, Feng Y. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expres- sion. J Obstet Gynaecol Res (2012) 38:1077-85. doi:10.1111/j.1447-0756.2011.01839.x
65. Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 125:458-69. doi:10.1016/j.ygyno.2012.01.009
66. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One (2013) 8:e61537. doi:10.1371/journal.pone.0061537
67. Malaguanera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, et al. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology (2014) 155:1207-21. doi:10.1210/en.2013-1925
68. Siegel DS, Hussein M, Belani C, Robert F, Galanis E, Richon VM, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 2:31. doi:10.1186/1756-8722-2-31
69. Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J (2014) 4:e182. doi:10.1038/bcj.2014.1
70. Bergada L, Sorolla A, Yeramian A, Eritja N, Mirantes C, Matias-Guiu X, et al. Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells. Mol Oncol (2013) 7:763-75. doi:10.1016/j.molonc.2013.03.003
71. Sarfstein R, Bruchim I, Fishman A, Werner H. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interactions with the insulin-like growth factor signaling pathway. PLoS One (2011) 6(9):e24468. doi:10.1371/journal.pone.0024468
72. Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma (2011) 2011(2011):402508. doi:10.1155/2011/402508
73. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2011) 104:68-74. doi:10.1038/sj.bjc.6605972
74. Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer (2012) 48:3027-35. doi:10.1016/j.ejca.2012.05.009
75. Nahor I, Abramovitch S, Engeland K, Werner H. The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res (2005) 15:388-96. doi:10.1016/j.ghir.2005.07.005